On April 27, 2022 Hubro Therapeutics reported that enrolment to cohort 2 (8 subjects) is completed and that all subjects have received their initial doses in the company’s phase 1 trial with FMPV-1 in healthy volunteers (Press release, Hubro Therapeutics, APR 27, 2022, View Source [SID1234613041]). Due to the high proportion of subjects with early detected T cell mediated immune responses seen in cohort 1, cohort 2 is being conducted with the same dose as used cohort 1. To date, FMPV-1 has been very well tolerated and it is expected that the immune responses should be relevant in MSI-H colorectal and gastric cancer. Data on cohort 2 immune responses are expected in Q2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!